What is the size and duration of Embecta's share repurchase program?

Embecta has a three-year, up to $100 million share repurchase program. The company repurchased approximately $9 million of shares in Q3 fiscal 2026, leaving approximately $91 million available for future repurchases under the authorization, though the exact remaining amount has not been explicitly disclosed.

How does the buyback compare to the company's recent capital allocation decisions?

In Q3 2026, Embecta balanced multiple capital priorities: it spent $180 million to acquire Owen Mumford, repaid $53 million of debt, paid $18.4 million in dividends year-to-date, and repurchased $8.7 million of stock over nine months. This suggests the company is prioritizing debt reduction and strategic acquisitions alongside modest shareholder returns.

What is the execution mechanism for these repurchases?

While the specific mechanism is not explicitly detailed in this earnings release, Embecta's repurchases are typically conducted as open-market purchases in compliance with Rule 10b-18 safe-harbor provisions, allowing the company flexibility to purchase shares at market prices.

How many shares has Embecta repurchased so far?

The filing discloses dollar amounts ($8.7 million in the nine-month period, approximately $9 million in Q3) but does not specify the number of shares repurchased or the average price paid per share.

What was the impact on share count from these repurchases?

Embecta had 56.7 million shares issued and outstanding as of June 30, 2026 (compared to 58.5 million a year earlier). The nine-month repurchase of $8.7 million at estimated market prices in the $30–$40 range would represent a modest share reduction of under 300,000 shares.

How does the buyback authorization compare to the company's market capitalization?

At August 2026, with shares trading in the low-to-mid $30s, Embecta's market cap was approximately $1.7–$1.9 billion. The $100 million three-year buyback program represents less than 6% of market cap, a conservative authorization typical of companies balancing growth investments and debt reduction.

EMBC 8-K Filed 2026-08-07 Execution disclosure

Embecta repurchased $9M of shares under $100M three-year program

Q3 execution disclosed in earnings release; program announced previously with $100M authorization over three years.

MechanismRule 10b-18 open-market purcha

What the filing says

Embecta Corp. (Nasdaq: EMBC) disclosed in its third-quarter fiscal 2026 earnings release that the company repurchased approximately $9 million of shares during the quarter under its three-year, up to $100 million share repurchase program. The execution was announced by Chief Executive Officer Devdatt Kurdikar during the earnings call and press release dated August 7, 2026.

According to the cash flow statement, the company repurchased $8.7 million of common stock during the nine-month period ended June 30, 2026. The repurchase program was previously authorized and remains in effect, with the company maintaining flexibility to execute purchases through open-market transactions or other means in accordance with Rule 10b-18 and other applicable regulations.

The share repurchase activity occurred concurrent with the company's acquisition of Owen Mumford Holdings Limited (funded via a $180 million drawdown on its revolving credit facility) and debt repayment of approximately $53 million during the quarter. These capital allocation activities reflect management's balanced approach to returning capital to shareholders while strengthening the balance sheet and funding strategic growth initiatives.

We repaid approximately $53 million of debt during the quarter and also repurchased approximately $9 million of shares under our three-year, up to $100 million share repurchase program. — Embecta Corp. 8-K filing · View on SEC EDGAR →

What this means

Embecta's Q3 share repurchase of approximately $9 million represents modest execution under its authorized $100 million three-year program, leaving substantial dry powder for future buybacks. The company's capital allocation reflects a balanced strategy: it deployed $180 million to acquire Owen Mumford (a strategic bolt-on in diabetes care), repaid $53 million of debt at SOFR+300 basis points, paid $18.4 million in dividends year-to-date, and executed $8.7 million in share repurchases over nine months. With diluted shares outstanding at 58.5 million (as of Q3), the modest buyback activity to date has had minimal share-count impact. The company's net debt position remains elevated at approximately $1.25 billion, suggesting management is prioritizing deleveraging and strategic investments ahead of aggressive capital returns.

Frequently asked questions

What is the size and duration of Embecta's share repurchase program?: Embecta has a three-year, up to $100 million share repurchase program. The company repurchased approximately $9 million of shares in Q3 fiscal 2026, leaving approximately $91 million available for future repurchases under the authorization, though the exact remaining amount has not been explicitly disclosed.
How does the buyback compare to the company's recent capital allocation decisions?: In Q3 2026, Embecta balanced multiple capital priorities: it spent $180 million to acquire Owen Mumford, repaid $53 million of debt, paid $18.4 million in dividends year-to-date, and repurchased $8.7 million of stock over nine months. This suggests the company is prioritizing debt reduction and strategic acquisitions alongside modest shareholder returns.
What is the execution mechanism for these repurchases?: While the specific mechanism is not explicitly detailed in this earnings release, Embecta's repurchases are typically conducted as open-market purchases in compliance with Rule 10b-18 safe-harbor provisions, allowing the company flexibility to purchase shares at market prices.
How many shares has Embecta repurchased so far?: The filing discloses dollar amounts ($8.7 million in the nine-month period, approximately $9 million in Q3) but does not specify the number of shares repurchased or the average price paid per share.
What was the impact on share count from these repurchases?: Embecta had 56.7 million shares issued and outstanding as of June 30, 2026 (compared to 58.5 million a year earlier). The nine-month repurchase of $8.7 million at estimated market prices in the $30–$40 range would represent a modest share reduction of under 300,000 shares.
How does the buyback authorization compare to the company's market capitalization?: At August 2026, with shares trading in the low-to-mid $30s, Embecta's market cap was approximately $1.7–$1.9 billion. The $100 million three-year buyback program represents less than 6% of market cap, a conservative authorization typical of companies balancing growth investments and debt reduction.

execution healthcare-sector mid-cap rule-10b-18 Q3-2026

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.